Labetuzumab govitecan

Labetuzumab govitecan is an antibody–drug conjugate that was investigated for the treatment of colorectal cancer. Labetuzumab has also been evaluated in patients with metastatic medullary thyroid carcinoma.
The parent antibody, labetuzumab, is a humanized IgG1 monoclonal antibody that selectively binds to carcinoembryonic antigen-related cell adhesion molecule 5. In the ADC, the antibody is covalently linked to SN-38, the active metabolite of the topoisomerase I inhibitor irinotecan.
The drug was developed by Immunomedics, Inc.